The Latest Medical News

A Summary of The Latest Medical News: Here’s a concise overview of the 2024 joint migraine-management update from the American Academy of Neurology (AAN) and American Headache Society (AHS). It replaces the 2012 guideline and integrates both time-tested therapies and newer, mechanism-based preventive options (notably CGRP-pathway treatments). 1. Acute (“rescue”) treatments • NSAIDs (ibuprofen, naproxen) and acetaminophen • Triptans (sumatriptan, rizatriptan, etc.) • Dihydroergotamine • Anti-emetics for nausea (metoclopramide, prochlorperazine) • Ditans (lasmiditan) and gepants (ubrogepant, rimegepant) for patients who can’t tolerate or don’t respond to triptans 2. Preventive treatments—established agents Indicated when patients suffer • ≥ 4 migraine days per month, or • 2–3 days/month with substantial disability, or • any frequency in “high-disability” patients First- or second-line options include: • Beta-blockers (propranolol, metoprolol) • Antiepileptics (topiramate, valproate) • Tricyclic antidepressants (amitriptyline) • Calcium-channel blockers (verapamil) 3. CGRP-pathway–targeted preventive therapies (newer agents) • Monoclonal antibodies against CGRP or its receptor (erenumab, fremanezumab, galcanezumab, eptinezumab) • Oral gepants (atogepant, rimegepant) approved for prevention Key advantages: rapid onset, favorable tolerability, few drug–drug interactions 4. When to choose CGRP-targeted therapy • Inadequate response or intolerable side effects from ≥ 2 first-line preventives • Contraindications to or poor adherence with oral meds • Patient preference for lower monitoring burden 5. Special considerations • Children and adolescents: Only select gepants and mAbs have pediatric labeling • Pregnancy/lactation: most CGRP agents are not recommended—stick with the lowest-effective dose of NSAIDs or consider nonpharmacologic approaches • Comorbidities: tailor choices to coexisting conditions (e.g., avoid beta-blockers in asthma; prefer CGRP mAbs if depression is prominent) 6. Nonpharmacologic and procedural options • Behavioral therapies (biofeedback, cognitive-behavioral therapy) • Neuromodulation devices (transcutaneous supraorbital, vagal nerve stimulation) • Occipital nerve block for refractory cases 7. Monitoring and follow-up • Track monthly headache days, severity, acute-med overuse • Reassess efficacy and tolerability after 2–3 months on any preventive agent • Taper or discontinue preventives after ≥ 6–12 months of stable remission Bottom line: Combine personalized selection of acute and preventive drugs with lifestyle modification, nonpharmacologic therapies, and—where appropriate—the new CGRP-pathway agents to achieve optimal migraine control. Help with your insurance? https://tally.so/r/n012P9